ABSTRACT Background: Children treated for severe acute malnutrition (SAM) are at risk of refeeding hypophosphatemia. Therapeutic diets have only recently become fortified with phosphorus to meet United Nations (UN) specifications, but to our knowledge no studies have investigated the effect. Objective: The aim was to assess concentrations and correlates of plasma phosphate (P-phosphate) at admission and during treatment and to identify correlates of changes in P-phosphate. Design: This was a prospective observational study in 6-to 59-mo-old children admitted for treatment of SAM to Mulago Hospital, Uganda. P-phosphate was measured at admission, on the second day of treatment with a therapeutic formula containing 75 kcal/100 mL and 560 mg phosphorus/L (F-75, Nutriset), at the start of the transition to a therapeutic formula containing 100 kcal/100 mL and 579 mg phosphorus/L (F-100; Nutriset), at day 2 of transition, and at discharge. Results: Among 120 children, mean 6 SD P-phosphate at admission was 1.04 6 0.31 mmol/L and increased by 0.43 (95% CI: 0.35, 0.52) mmol/L during the first 2 d and more slowly toward discharge. Most (79%) children experienced their lowest P-phosphate concentration at admission, and none developed severe hypophosphatemia. P-phosphate was lowest in children with edema and with elevated C-reactive protein, and a lower increase was seen with increasing caretaker-reported severity of illness. Partially or fully replacing F-75 with rice porridge (i.e., a local practice to reduce diarrhea) during the first 2 d of stabilization was associated with a 0.34-mmol/L (95% CI: 0.18, 0.50 mmol/L) lower increase in P-phosphate during the same first 2 d. Conclusions: F-75, which complies with UN specifications and provides 73 mg phosphorus $ kg
INTRODUCTION
Children with severe acute malnutrition (SAM) 7 require immediate medical care and nutritional support, which puts them at risk of refeeding syndrome. During refeeding, the body converts from catabolism to anabolism and a shift occurs from fat to carbohydrate metabolism, which elicits insulin release and increases cellular uptake of electrolytes, including phosphate (i.e., the natural occurring form of the mineral phosphorus). If the diet contains insufficient amounts of phosphorus, this may exacerbate phosphorus depletion. Serum electrolytes are not routinely monitored; therefore, adequate phosphorus content in the diet is essential to prevent depletion.
To prevent refeeding syndrome, the WHO's guideline on inpatient management of SAM (1) includes a stabilization phase with a low-energy formula (F-75; Nutriset), as well as a gradual transition to F-100 (Nutriset) or ready-to-use therapeutic food (transition phase). Studies on refeeding hypophosphatemia have focused on the first days of treatment, but studies on the effect of transition-phase feeding on plasma phosphate (P-phosphate) concentrations are lacking.
F-75 and F-100 can be made either from a premixed powder or with local ingredients with an added vitamin-mineral mix (including potassium and magnesium but not phosphorus). Therefore, the phosphorus content of locally prepared formula depends solely on the ingredients used, with milk products being the main source. Because F-75 contains relatively little milk, its ingredients provide limited amounts of phosphorus and substantially less than the 60 mg $ kg 21 $ d 21 recommended by the WHO (1) . This combination of a high proportion of energy from carbohydrate and the low phosphorus content may be problematic (2) .
Studies in children with SAM found low blood phosphate at admission and a further decline, reaching a nadir within the first couple of days, that was associated with increased mortality (3, 4) . However, in most studies, the children were not treated according to current WHO guidelines (1, 5) or with the use of the premixed products commonly used today (6, 7) . Following new UN procurement specifications for F-75 (6), extrinsic phosphorus, in the form of a phosphorus salt, has been added to the premixed product at an amount of 560 mg phosphorus/L of F-75 (i.e., a child fed 130 mL F-75 $ kg 21 Table 1) . We aimed to assess P-phosphate on admission, during stabilization, and during transition as well as to explore correlates of changes in P-phosphate in children treated with premixed F-75 and F-100, which comply with the UN specifications.
METHODS

Study setting and participants
This was a prospective observational study in children aged 6-59 mo who were admitted for treatment of SAM between October 2012 and February 2013. It was conducted at Mwanamugimu Nutrition Unit (MNU), Mulago Hospital, in Kampala, Uganda, the main national treatment center for children with complicated SAM. Children received standard treatment on the basis of the Ugandan National Protocol for Integrated Management of Acute Malnutrition (8) with the use of the following therapeutic diets: F-75 (102.5 g/sachet, Nutriset), which contains 560 mg phosphorus/L, and F-100 (114 g/sachet, Nutriset), which contains 579 mg phosphorus/L. In the stabilization phase, children were given F-75. All children were given parenteral antibiotics, usually ampicillin and gentamycin. Children with dehydration were rehydrated with oral rehydration solution for malnutrition (ReSoMal, 42 g/sachet; Nutriset). When children were clinically stable, their appetite returning, and edema had started to resolve, they entered the transition phase and were given F-100. When the children were clinically well, had a good appetite, and had no edema, they were discharged for outpatient treatment. All of the biological mothers were offered routine counseling and testing for HIV following WHO guidelines (9) , and if positive or if the biological mother was not present, the child was tested. In antibodypositive children aged ,18 mo the diagnosis was confirmed by using polymerase chain reaction.
At the time of the study, a few local modifications of the Integrated Management of Acute Malnutrition protocol were practiced at the MNU. If a child had diarrhea and intolerance to the milk-based feedings was suspected, the diets were fully or partially replaced by rice porridge for some of the days. Furthermore, most children were given 1 daily serving of corn-soy porridge after entering the transition phase, and during the last days before discharge all of the mothers participated in cooking classes where they prepared energy-dense dishes for the children using locally available foods.
Children between 6 and 59 mo of age admitted with SAM were included in the study if it was confirmed that their weight-forlength z score (WLZ) was ,-3 with the use of the WHO Child Growth Standard (10), midupper arm circumference (MUAC) was ,11.5 cm, or bilateral pitting edema was present and if the child was living close to the hospital and the caretaker gave informed consent. Children were excluded if any of the following criteria were met: significant congenital malformations, shock or severe respiratory distress at admission, hemoglobin ,40 g/L, or a body weight ,4.5 kg. Severe conditions such as sepsis, HIV, and tuberculosis were not reasons for exclusion. Inclusion was not possible during weekends, during public holidays, and at night.
Data collection
At admission, a structured questionnaire was used to obtain demographic information and feeding and medical history. Caretakers were asked about symptoms present and to rate the perceived severity of their child's illness on a visual analog scale from 1 to 10. A physical examination was performed, including measurement of vital signs (pulse, respiratory rate, capillary refill time), hepatomegaly, and pitting edema. Length was measured by using an infant length board and MUAC determined by using color-coded tape (S0145620 MUAC, CHILD 11.5 red/pac-50, UNICEF), both to the nearest 1 mm. Body weight was measured daily by using a digital scale to the nearest 100 g.
Blood sampling was performed at 5 time points during the children's stay in the hospital: at admission, at day 2 after starting refeeding with F-75, just before transition to F-100, at day 2 of transition, and at the day of discharge to outpatient treatment. Powder-free gloves were used for blood sampling to prevent mineral contamination. At each of the 5 time points, 1 mL blood was collected into heparinized evacuated tubes (BD Vacutainer). Hemoglobin was measured at admission and discharge by using HemoCue (Hb 201+). Plasma was separated and frozen at 2208C until analysis, and P-phosphate was measured at Ebenezer Ltd. Clinical Laboratory (ISO 15189, Testing Laboratory M0221) with the molybdate UV method by using the Cobas Integra 400 Plus automated system. The reference range provided by the laboratory was 1.6-3.5 mmol/L for infants aged between 2 and 12 mo and 1.1-2.0 mmol/L for children .12 mo old. At admission and discharge, another plasma sample was obtained from an evacuated cell preparation tube with citrate. This was frozen at 2808C until the end of the data collection and shipped to Denmark on dry ice, where C-reactive Nutrition information for F-75 and F-100 (Nutriset, France) was obtained from the packages. Nutrition information for the rice porridge was obtained from foodcomp.dk. protein (CRP) and a 1 -acid glycoprotein (AGP) were determined at the University of Copenhagen's Department of Nutrition, Exercise, and Sports with the use of ABX Pentra 400 (Horiba). Study staff monitored the children daily, recording weight, MUAC, vital signs, degree of edema, frequency and consistency of stools, presence of vomiting, type and amount of feeding given, whether ReSoMal was given, and whether a nasogastric tube was used for feeding.
Control group
Healthy children with a WLZ .21 and aged 6-59 mo were recruited from children of hospital staff and siblings of hospitalized children. Physical examinations and anthropometric measurements similar to those described in the study patients were conducted, and one venous blood sample was drawn and analyzed as described above.
Ethics
The study was approved by Makerere University School of Medicine's Research Ethics Committee and the Uganda National Council for Science and Technology, and consultative approval was obtained from the Danish National Board of Research Ethics. All of the caretakers gave oral and written consent to participate after receiving oral and written information about the study in English and Luganda.
Data handling and statistical analysis
Rather than testing a single hypothesis, the study used an explorative approach to describe the changes in P-phosphate during recovery and the role of various exposure variables such as the presence of edema, HIV, etc. With 120 children in the study, and with an expected 50% with edema, we would have 80% power to detect a difference of $0.5 SDs in P-phosphate, with a 5% significance level. Similarly, with a control group of 30 children, we would have 80% power to detect differences of $0.6 SDs in P-phosphate between children with SAM and control children.
Data were double-entered in EpiData and analyzed by using Stata version 12 (StataCorp). Anthropometric z scores based on the 2006 WHO Child Growth Standard were computed (11) by using the lowest weight recorded during admission to obtain edema-free weight and taking into account that length was measured even in children .2 y old (i.e., height was estimated by subtracting 0.7 cm from the recumbent length). Extreme anthropometric values were not removed if they were consistent when compared with measurements on subsequent days and also compared with measurements from other outcomes (e.g., those with extreme z scores should also have a very low MUAC).
The 2-sample t test, Wilcoxon's Mann-Whitney test, and the chisquare test were used to evaluate differences in mean P-phosphate, age, and sex distributions, respectively, between children with SAM and control children. Linear regression was used to identify correlates of P-phosphate. When exploring correlates of change in P-phosphate from admission to 2 d after admission and from the start of transition to 2 d after transition, we used linear regression with P-phosphate as the dependent variable, adjusted for P-phosphate at admission and the start of transition, respectively. The change over time in P-phosphate was analyzed by using a multilevel linear mixed-effects regression model with child-specific random effects, because repeated measurements per child were included in the analysis.
The timing of blood sample collection relative to the treatment phase was included as a fixed effect (i.e., stabilization day 0 and stabilization day 2, transition day 0 and transition day 2, and day of discharge). In case stabilization day 2 and transition day 0 coincided, the resulting observations were taken to reflect both phases. All models included an adjustment for age and sex. Models were checked by visual inspection of standardized residual plots.
RESULTS
As previously reported (12, 13) , among the 120 children admitted the median age was 16 (IQR: 13, 22) mo, 38% were 1 n = ,120 for some variables. AGP, a 1 -acid glycoprotein; CRP, Creactive protein; LAZ, length-for-age z score; MUAC, mid-upper arm circumference; VAS, visual analog scale; WAZ, weight-for-age z score; WLZ, weight-for-length z score.
2 Median; IQR in parentheses (all such values). 3 Mean 6 SD (all such values). 4 z Scores were computed for all children on the basis of the lowest weight recorded (after loss of edema).
5 Able to consume initial prescribed feeding. 6 According to the mother or caretaker, evaluated on a VAS from 1 to 10. 7 Only among children aged ,24 mo.
girls, 64% had edema, and 20 of 104 children tested for HIV were positive (19%) ( Table 2 ). The median duration of hospital admission was 19 d, with 4 d in the stabilization phase (i.e., admission to transition day 0). Of the 120 children, 100 (83%) were followed until death or discharge (Figure 1) . At admission, the mean 6 SD concentration of P-phosphate was 1.04 6 0.31 mmol/L, which was low compared with 1.98 6 0.38 mmol/L in 25 healthy children (P , 0.001) of similar age and sex distribution [median (IQR) age: 16 (11, 25) mo; 45% girls; P = 0.73 and P = 0.52, respectively]. P-phosphate was below the age-specific cutoff that defined low values in 37% of the patients but was not below this cutoff in any of the healthy children.
Mean P-phosphate increased by 0.43 (95% CI: 0.35, 0.52) mmol/L during the first 2 d of treatment and then more slowly through the transition phase to discharge (Figure 2) . At discharge, P-phosphate was below the age-specific cutoff defining low values in 6% of the patients, and the mean was only slightly lower than in healthy children (1.71 compared with 1.98 mmoL/L; P = 0.002). The majority of children (79%) experienced their lowest P-phosphate concentration at admission.
Correlates of P-phosphate and change with treatment
At admission, hemoglobin was positively correlated with P-phosphate, whereas edema, WLZ, and elevated plasma CRP were negatively correlated ( Table 3) . For edema, the regression coefficient of 20.13 reflects a 0.13-mmol/L lower P-phosphate concentration among children with edema than in those without edema. After adjustment for edema (data not shown), the correlation with WLZ was not significant (B = 20.031; 95% CI: 20.077, 0.015; P = 0.19).
Maternal perception of the severity of illness and presence of oral thrush were both negative correlates of change in P-phosphate during the first 2 d of the stabilization phase. For maternal perception of the severity of illness, the regression coefficient of 20.043 mmol/L (95% CI: 20.084, 20.003 mmol/L) reflects a 0.043-mmol/L lower increase in P-phosphate per unit increase on the visual analog scale. For oral thrush, the regression were correlates of P-phosphate concentration at the start of the transition phase. During the first 2 d of transition to F-100, children with an enlarged liver had a 0.162-mmol/L (95% CI: 0.009, 0.315 mmol/L) higher increase in P-phosphate than did those without. Feeding via a nasogastric tube or administration of ReSoMal was not associated with a change in P-phosphate during the first days of stabilization or in the transition phase (data not shown).
Feeding rice porridge
Diarrhea was present in 45 children during the first 2 d of the stabilization phase and in 31 children during the first 2 d of the transition phase. Diarrhea during the first 2 d of admission was associated with a 0.14 mmol/L (95% CI: 20.01, 0.30 mmol/L) reduced increase in P-phosphate, but this was not significant (P = 0.064; data not shown).
In 25% (29) of the children, F-75 was partially or completely replaced by rice porridge on one or both of the first 2 d of stabilization. In 28% (27) of children, F-100 was partially replaced by rice porridge in the first 2 d of the transition phase. Of the 27 children fed rice porridge during the first days of transition to F-100, 13 had also been fed rice porridge during the first days of the stabilization phase.
Feeding rice porridge during the first 2 d of stabilization was associated with a 0.34 mmol/L (95% CI: 0.18, 0.50 mmol/L; FIGURE 2 Mean P-phosphate concentrations during treatment in 120 children with severe acute malnutrition. Change over time in P-phosphate was analyzed by using a multilevel linear mixed-effects regression model that included timing of blood sample, age, and sex as fixed effects and children as random effects. Values are estimated means and 95% CIs adjusted for sex and age at admission (S-day0; n = 115), after 2 d in the stabilization phase (S-day2; n = 94), at the start of the transition phase (T-day0; n = 87), after 2 d in the transition phase (T-day2; n = 87), and at discharge (D; n = 68). P-phosphate, plasma phosphate. Values are coefficients (B) and 95% confidence limits (95% CIs) adjusted for sex and age. Correlates of P-phosphate were identified by using linear regression models. When exploring correlates of change, P-phosphate at day 2 was the dependent variable and P-phosphate at admission and the start of transition, respectively, was the independent variable. *Significant, P , 0.05. AGP, a 1 -acid glycoprotein; CRP, C-reactive protein; LAZ, length-for-age z score; MUAC, mid-upper arm circumference; VAS, visual analog scale; WLZ, weight-for-length z score. z Scores were computed for all children on the basis of the lowest weight recorded (after loss of edema). 3 Able to consume initial prescribed feeding. 4 According to the mother or caretaker, evaluated on a VAS from 1 to 10. P , 0.001) reduced increase in P-phosphate (Figure 3) , which persisted after adjustment for diarrhea during the first 2 d (B = 0.39 mmol/L; 95% CI: 0.22, 0.57 mmol/L; P , 0.001; data not shown in Figure 3) . All of the children (n = 8) who experienced a decrease in P-phosphate from admission to day 2 had been given rice porridge during their first 2 d of treatment. In contrast to the stabilization phase, feeding rice porridge during the first 2 d of transition to F-100 was not associated with changes in P-phosphate (B = 20.17 mmol/L; 95% CI: 20.41, 0.07 mmol/L; P = 0.16).
DISCUSSION
To our knowledge, this is the first study to present data on P-phosphate in children stabilized with F-75, which complies with UN specifications, and to present data on changes in P-phosphate during the transition phase.
P-phosphate at admission
Similar to other studies, we found low P-phosphate concentrations in children with SAM at admission and the lowest concentrations in children with edema (3, 4, 14-16 ). The difference in P-phosphate between children with and without edema leveled out as children recovered from their edema. The trend for lower P-phosphate concentrations with higher WLZ may be explained by less wasting in edematous children, because the association disappeared when edema was controlled for. It may be speculated that low P-phosphate could be involved in the pathogenesis of edema in malnutrition, a relation that deserves investigation in future studies.
The lower P-phosphate concentrations in children with elevated plasma CRP suggests that inflammation may lower concentrations of P-phosphate. Hypophosphatemia has been reported to occur in pediatric patients with acute infections (17) and children with SAM and sepsis (18) , but the mechanism is unknown.
Change in P-phosphate with treatment
In contrast to previous studies, we found increasing concentrations of P-phosphate throughout the treatment period, toward concentrations that were close to those in healthy children. Whereas other studies reported a "phosphate nadir" on day 2 of treatment (3, 4, 18) , only a few children in our study experienced a decrease in P-phosphate during the first days of treatment; this was not seen in any child who received F-75 only during the stabilization phase. The previous studies were conducted in children who received locally prepared diets (3, 4) without extra phosphorus; thus, the content was determined by the ingredients. In one study (3), children with SAM were stabilized with local equivalents of F-75 with either dried skim milk or egg white as protein sources, and with the addition of a vitamin and mineral mix not including phosphorus. P-phosphate decreased in children fed the egg white-based diet, which provided 2 mg phosphorus $ kg 21 $ d
21
, but remained unchanged in children fed the milk-based diet, which provided 35 mg $ kg 21 $ d
, emphasizing the role of diet in hypophosphatemia.
In other patient groups undergoing refeeding, such as verylow-birth-weight infants (19) or patients with anorexia nervosa (20, 21) , P-phosphate is usually monitored and phosphorous is given if low. However, in most treatment centers for children with SAM, it is not feasible to monitor electrolyte disturbances. Therefore, standard treatment should be trusted to prevent hypophosphatemia in all treated children without the need for monitoring of P-phosphate.
The WHO guideline from 1999 on the management of children with SAM (1) recommends a daily intake of 60 mg (2.0 mmol)/kg body weight during the initial days of treatment. However, this is not possible when feeding F-75 prepared according to the recipe provided in the same guideline. In line with the WHO recommendation, the procurement specifications of UN agencies for premixed F-75 require a phosphorous content corresponding to an intake of 65-130 mg phosphorus $ kg 21 To reach this amount, phosphorus is added in the form of a mineral salt. The use of mineral salts as a source of phosphorus has been questioned because of low solubility (22) . However, our data indicate that it is sufficient to allow an increase in P-phosphate with treatment. Whether further fortification could improve outcomes remains to be investigated.
Children whose F-75 diet was partially or completely replaced by rice porridge during the first 2 d of treatment had a less pronounced increase in P-phosphate. Because rice porridge was given to children with diarrhea, it is possible that this association was confounded by indication, i.e., it may be due to diarrhea rather than rice porridge. However, some observations suggest that the diet itself could have a negative effect on P-phosphate concentrations. First, reported diarrhea was not associated with lower P-phosphate concentrations, and observed diarrhea during the first days was only marginally associated with a lower increase during treatment, an association that disappeared when the use of rice porridge was controlled for. Second, children given rice porridge did not have lower P-phosphate concentrations on admission before starting treatment. If the lower increase in P-phosphate was due to diarrhea, it would be expected that they also had lower concentrations from the beginning. Third, when comparing the nutrient content of rice porridge and F-75 it is plausible that rice porridge could have an adverse effect on P-phosphate concentrations. Rice porridge, made from 1500 mL water and 200 g rice flour, contained an estimated 13 mg/100 mL, almost no fat, and most of the energy derived from carbohydrate (Table 1) . This could induce a greater insulin response, increasing the influx of phosphate into cells. It was the impression among clinicians at the MNU that rice porridge reduced the intensity of diarrhea, although this has never been formally evaluated. Other centers advocate for ricebased oral rehydration solution to reduce stool output in diarrhea (23, 24) . Even so, the association of rice porridge with a lower increase in P-phosphate is a cause of concern, and its use was stopped at the MNU after the completion of our study.
Oral thrush and increased caretaker-reported severity of illness on a visual analog scale were also associated with a less pronounced increase in P-phosphate during the first days of treatment. This could indicate that children with critical illness may respond less well to treatment in terms of increasing P-phosphate concentrations.
During the transition phase, few factors were associated with the change in P-phosphate. This could be due to low power but could also indicate that P-phosphate is more stable in this period. Interestingly, a greater increase in P-phosphate during the first days of transition was seen in children with liver enlargement.
Strengths and limitations
This is the first study, to our knowledge, to describe the pattern of P-phosphate in a larger group of children with SAM who were receiving standard premixed F-75 and F-100 fortified with phosphorus and with deviations from standard treatment. We aimed to reduce information bias by ensuring that laboratory technologists who determined P-phosphate concentrations were unaware of the clinical and other biochemical characteristics of the children.
There are several limitations to the study. First, the observational design precludes conclusions about causality. Second, because we did not adjust for multiplicity, some of the associations may be due to chance. Third, loss to follow-up was considerable due to deaths and to caretakers leaving the unit with their children before being discharged. It is plausible that children who were lost to follow-up were sicker than those who stayed in the study. Fourth, the local practice of feeding rice porridge to children with diarrhea is not part of any established treatment protocol, which limits the generalizability of our results to other children with SAM.
Conclusions
Nutritional rehabilitation with premixed F-75 that complies with UN specifications seems to be effective in terms of preventing hypophosphatemia during refeeding. An update of the recipes for local preparation of F-75 suggested in the WHO (1999) manual could be considered, and phosphorus could be added to the standard mineral-vitamin mix used to prepare F-75 based on local ingredients. Randomized trials that compare F-75 formulas with different contents of phosphorus are needed to evaluate whether further fortification could reduce morbidity and mortality. We recommend that any substitutes of F-75 are used with great care, particularly if their mineral content is suboptimal than in standard diets.
